Olaparib, PARP1 inhibitor in ovarian cancer

Bibliography

• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69-90; Erratum, CA Cancer J Clin 2011;61:134
   PubMed Web of Science ®Google Scholar
• Dinh P, Harnett P, Piccart-Gebhart MJ, New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 2008;67:103-12
   PubMed Web of Science ®Google Scholar
• Heintz A, Odicino F, Maisonneuve P, Carcinoma of the ovary. Int J Gynaecol Obstet 2006;95(Suppl 1):S161-92
   PubMed Web of Science ®Google Scholar
• Chi DS, Eisenhauer EL, Zivanovic O, Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114(1):26-31
   PubMed Web of Science ®Google Scholar
• Szabo C, Zingarelli B, O'Connor M, DNA strand breakage, activation of poly(ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996;93:1753-8
   PubMed Web of Science ®Google Scholar
• de Murcia JM, Niedergang C, Trucco C, Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997;94:7303-7
   PubMed Web of Science ®Google Scholar
• Bryant HE, Schultz N, Thomas HD, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434(7035):913-17
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Favalli G, Gadducci A, Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009;27(28):4642-8
   PubMed Web of Science ®Google Scholar
• Markman M. Why study third-, fourth-, fifth-,. line chemotherapy of ovarian cancer? Gynecol Oncol 2001;83(3):449-50
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Elattar A, Cerbinskaite A, Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumour and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010;16(8):2344-51
   PubMed Web of Science ®Google Scholar
• Menear KA, Adcock C, Boulter R, 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51(20):6581-91
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Inhibition of poly(ADP-ribose) polymerase in tumours from BRCA mutation carriers. N Engl J Med 2009;361:123-34
   PubMed Web of Science ®Google Scholar
• Sessa C. Update on PARP1 inhibitors in ovarian cancer. Ann Oncol 2011;22(Suppl 8):S72-6
   Google Scholar
• Fong PC, Yap TA, Boss DS, Poly(ADP)-ribose polymerase inhibition:frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-19
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Nokihara H, Yamada Y, A phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumours. Cancer Sci 2012;103(3):504-9
   PubMed Web of Science ®Google Scholar
• Palma JP, Rodriguez LE, Bontcheva-Diaz VD, The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer Res 2008;28(5A):2625-35
   PubMed Web of Science ®Google Scholar
• Donawho CK, Luo Y, Luo Y, ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumour models. Clin Cancer Res 2007;13(9):2728-37
   PubMed Web of Science ®Google Scholar
• Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010;22(5):473-80
   PubMed Web of Science ®Google Scholar
• Samol J, Ranson M, Scott E, Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, Olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumours: a phase I study. Invest New Drugs 2011;30(4):1493-500
   PubMed Web of Science ®Google Scholar
• Khan OA, Gore M, Lorigan P, A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 2011;104:750-5
   PubMed Web of Science ®Google Scholar
• Dent RA, Lindeman GJ, Clemons M, Safety and efficacy of the oral PARP inhibitor Olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2011;28(15S):abstract 1018
   Google Scholar
• Rajan A, Carter CA, Kelly RJ, A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumours. Clin Cancer Res 2012;18(8):2344-51
   PubMed Web of Science ®Google Scholar
• Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000;460(1):1-15
   PubMed Web of Science ®Google Scholar
• Rajan A, Carter CA, Kelly RJ, A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 2012;18(8):2344-51
   PubMed Web of Science ®Google Scholar
• Dean E, Middleton MR, Pwint T, Phase I study to assess the safety and tolerability of Olaparib in combination with Bevacizumab in patients with advanced solid tumours. Br J Cancer 2012;106(3):468-74
   PubMed Web of Science ®Google Scholar
• Chan N, Bristow RG. Contextual'' synthetic lethality and/or loss of heterozygosity: tumour hypoxia and modification of DNA repair. Clin Cancer Res 2010;16:4553-60
   PubMed Web of Science ®Google Scholar
• Martinek I, Haldar K, Gaitskell K, DNA-repair pathway inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2010(6):CD007929
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376(9737):245-51
   PubMed Web of Science ®Google Scholar
• Kaye SB, Lubinski J, Matulonis U, Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30(4):372-9
   PubMed Web of Science ®Google Scholar
• Gordon AN, Fleagle JT, Guthrie D, Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19(14):3312-22
   PubMed Web of Science ®Google Scholar
• Adams SF, Marsh EB, Elmasri W, A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol Oncol 2011;123(3):486-91
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Tischkowitz M, Mackay H, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet 2011;12:852-61
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer 2011;47(Suppl 3):S116-30
   PubMedGoogle Scholar
• Konstantinopoulos PA, Spentzos D, Karlan BY, Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 2010;28(22):3555-61
   PubMed Web of Science ®Google Scholar
• Banerjee S, Kaye S. PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond. Curr Oncol Rep 2011;13(6):442-9
   PubMedGoogle Scholar
• Lee SA, Roques C, Magwood AC, Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression. DNA Repair (Amst) 2009;9:170-81
   Google Scholar
• Skehan P, Storeng R, Scudiero D, New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12
   PubMed Web of Science ®Google Scholar
• Ang J, Yap TA, Fong P, Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). J Clin Oncol 2010;28(15s Suppl):abstract 5041
   Google Scholar
• Norquist B, Wurz KA, Pennil CC, Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15
   PubMed Web of Science ®Google Scholar